Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
BDSI is in the long-term up 128% above S&P in 1 year.
Description: BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in patients with cancer; and BEMA Buprenorphine that is in Phase III trial for the treatment of chronic pain in a mixed opioid naïve and opioid experienced population. The company is also involved in the development of BUNAVAIL for the maintenance treatment of opioid dependence; and Clonidine Topical Gel for the treatment of painful diabetic neuropathy. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine; and license agreement with Arcion Therapeutics.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.35||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-5.98%||Sales Growth - Q/Q||412.53%||P/E||-6.57|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-70.05%||ROE||-115.89%||ROI||-109.33%|
|Current Ratio||2.42||Quick Ratio||2.34||Long Term Debt/Equity||0.05||Debt Ratio||0.59|
|Gross Margin||82.95%||Operating Margin||-150.93%||Net Profit Margin||-184.52%||Dividend Payout Ratio|
|Cash From Financing Activities||-1.86 M||Cash From Investing Activities||-140 K||Cash From Operating Activities||-5 M||Gross Profit||11.93 M|
|Net Profit||-8.19 M||Operating Profit||-7.8 M||Total Assets||82.47 M||Total Current Assets||71.74 M|
|Total Current Liabilities||29.59 M||Total Debt||10.26 M||Total Liabilities||32.62 M||Total Revenue||13.05 M|
|High 52 week||4.24||Low 52 week||1.7||Last close||4.24||Last change||2.17%|
|RSI||87.12||Average true range||0.22||Beta||0.68||Volume||448.88 K|
|Simple moving average 20 days||17.61%||Simple moving average 50 days||16.38%||Simple moving average 200 days||43.4%|
|Performance Week||6%||Performance Month||19.44%||Performance Quart||13.98%||Performance Half||51.43%|
|Performance Year||63.08%||Performance Year-to-date||14.59%||Volatility daily||4.48%||Volatility weekly||10.01%|
|Volatility monthly||20.51%||Volatility yearly||71.06%||Relative Volume||117.27%||Average Volume||642.39 K|
|New High||New Low|
2019-03-22 18:24:00 | Lifshitz & Miller LLP Announces Investigation of Alta Mesa Resources, Inc., American Renal Associates LLC, Belden, Inc., BioDelivery Sciences, Inc., Blue Valley Bank Corp., Bridgepoint Education, Inc., and Care.com, Inc.
2019-03-21 17:45:09 | BioDelivery Sciences International BDSI Gains But Lags Market: What You Should Know
2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse
2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up
2019-03-14 23:51:23 | Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT
2019-03-14 20:20:00 | Biodelivery Sciences International Inc BDSI Q4 2018 Earnings Conference Call Transcript
2019-03-14 19:45:29 | BioDelivery: 4Q Earnings Snapshot
2019-03-14 16:05:00 | BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
2019-03-14 14:30:00 | BioDelivery Sciences International, Inc. to Host Earnings Call
2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma
2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK
2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
2019-03-11 10:00:02 | What Makes BioDelivery Sciences International BDSI a Strong Momentum Stock: Buy Now?
2019-03-11 09:56:01 | Will the Decade-Old Bull Market Momentum Last? 5 Picks
2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?
2019-03-05 16:06:09 | What's in the Cards for Corbus CRBP This Earnings Season?
2019-03-05 08:44:01 | REGENXBIO RGNX in Focus: Stock Moves 5.1% Higher
2019-03-04 23:40:04 | Champions Oncology CSBR Q3 Earnings: What's in Store?
2019-03-04 23:34:04 | What's in the Cards for Novavax NVAX This Earnings Season?
2019-03-04 08:58:01 | What's in the Cards for Aeterna AEZS This Earnings Season?
2019-03-01 14:20:07 | Endo ENDP Q4 Earnings & Revenues Beat Estimates, Shares Up
2019-03-01 11:59:04 | Amicus FOLD Reports Wider-than-Expected-Loss for 2018
2019-03-01 10:27:03 | The Meet Group MEET to Report Q4 Earnings: What's in Store?
2019-02-28 11:12:04 | Horizon Pharma's HZNP Stock Up on Q4 Earnings & Sales Beat
2019-02-27 07:19:12 | Editas EDIT to Report Q4 Earnings: What's in the Cards?
2019-02-27 07:13:12 | Jazz Pharma JAZZ Q4 Earnings & Sales Beat, Stock Up 8%
2019-02-27 06:24:11 | 5 Affordable Breakout Stocks for Superlative Returns
2019-02-25 07:57:12 | What's in the Cards for Nektar NKTR This Earnings Season?
2019-02-22 16:53:09 | Amgen Starts Phase III Enrollment for Heart Failure Drug
2019-02-22 16:43:09 | What's in Store for Vericel VCEL This Earnings Season?
2019-02-22 16:36:09 | What's in Store for Teladoc's TDOC Q4 Earnings?
2019-02-22 14:46:07 | bluebird BLUE Q4 Earnings Beat Estimates, Revenues Up Y/Y
2019-02-22 09:23:02 | BioMarin BMRN Q4 Earnings & Sales Miss, Shares Decline
2019-02-21 09:34:02 | Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
2019-02-21 07:45:00 | BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
2019-02-20 09:45:02 | Key Factors to Know Ahead of TransEnterix TRXC Q4 Earnings
2019-02-20 09:12:00 | 3 Small Biotechs to Watch as Earnings Season Winds Down
2019-02-20 07:41:12 | Ultragenyx RARE Posts Narrower-Than-Expected Loss in Q4
2019-02-19 10:07:03 | What's in Store for Sangamo SGMO This Earnings Season?
2019-02-19 07:20:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Procter & Gamble, Hertz Global, NN, Omnicell, BioDelivery Sciences International, and Movado Group — New Research Emphasizes Economic Growth
2019-02-18 08:16:01 | What's in the Cards for Amarin AMRN This Earnings Season?
2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock
2019-02-15 10:29:03 | Acorda ACOR Q4 Earnings and Revenues Surpass Estimates
2019-02-15 08:54:01 | Key Factors Likely to Shape CVS Health's CVS Q4 Earnings
2019-02-14 10:45:03 | The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna